Clinical Trials Logo

Clinical Trial Summary

The purpose of this trial is to test if delgocitinib cream is effective at treating chronic hand eczema (CHE) and what side effects it may have, in children aged 12-17. There will be a range of assessments that rate the severity and extent of CHE symptoms, general health and quality of life. Delgocitinib is a cream that suppresses specific processes in the body's response to diseases like CHE, such as inflammation. The trial will last up to 22 weeks and has a 1-4 week screening period, a 16 week treatment period and a 2 week follow up period. During the treatment period each child will use either delgocitinib cream or a cream vehicle twice a day. Which cream each child receives is chosen randomly by a computer. The cream vehicle is made of the same ingredients as the delgocitinib cream except for the active medical ingredient. There will be 8 visits with the trial doctor.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05355818
Study type Interventional
Source LEO Pharma
Contact Clinical Disclosure
Phone (+1) 877-557-1168
Email disclosure@leo-pharma.com
Status Recruiting
Phase Phase 3
Start date July 14, 2022
Completion date December 17, 2024

See also
  Status Clinical Trial Phase
Withdrawn NCT05545215 - Prospective Real-World Clinical Investigation on Dexyane Med® in Adults With Chronic Hand Eczema
Completed NCT05486117 - Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema Phase 1
Recruiting NCT06004050 - A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema Phase 3
Recruiting NCT05682859 - Treatment of Chronic Hand Eczema With Oral Roflumilast (HERO) Phase 4
Recruiting NCT05994976 - Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
Completed NCT03683719 - Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema Phase 2
Completed NCT04872101 - Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2) Phase 3
Completed NCT01482663 - Chronic Hand Eczema - Self-management and Prognosis N/A
Completed NCT04871711 - Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema Phase 3
Recruiting NCT05026554 - Characterization of Chronic Hand Eczema
Completed NCT05259722 - A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema Phase 3
Recruiting NCT03861455 - Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids Phase 2
Completed NCT04949841 - Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials Phase 3
Completed NCT03246776 - Microbial Colonization and Change of Chronic Keratinized Hand Eczema After Using Halometasone Triclosan Phase 4
Not yet recruiting NCT06283550 - Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy Phase 2
Completed NCT04378569 - Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema Phase 1/Phase 2